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Abstract
Purpose The association between metformin use and renal
function needs further to be elucidated since data are insuffi-
cient whether metformin affects renal function in higher risk
populations such as after ST-elevation myocardial infarction
(STEMI).
Methods We studied 379 patients included in the GIPS-III
trial in which patients without diabetes or renal dysfunction,
who underwent primary percutaneous coronary interventions
(PCI) for STEMI, were randomized to metformin 500 mg or
placebo twice daily for four months. At baseline and at seven
scheduled visits up to four months after PCI, estimated glo-
merular filtration rate (eGFR) was determined (2582 values).
Contrast-induced acute kidney injury (CI-AKI) was defined as
an increase in serum creatinine of ≥0.3 mg/dl or 25 % rise
within 48 h after PCI.
Results At all visits, the mean eGFR was similar in patients
randomized to metformin or placebo. Over the four month
period, mixed-effect repeated-measures model analysis
showed a least-squares mean ± standard error change in eGFR
of -5.9±0.8 ml/min/1.73 m2 in the metformin group and −7.1
±0.8 ml/min/1.73 m2 in the control group (P=0.27 for overall
interaction). The incidence of CI-AKI was 14.8 %; 29
(15.2 %) patients in the metformin group versus 27 (14.4 %)
controls (P=0.89). After adjustment for covariates, metformin
treatment was not associated with CI-AKI (odds ratio: 0.96,
95%CI 0.52−1.75, P=0.88).
Conclusion We conclude that initiation of metformin shortly
after primary PCI has no adverse effect on renal function in
patients without diabetes or prior renal impairment, further
providing evidence of the safety of metformin use after myo-
cardial infarction and subsequent contrast exposure.
Keywords Metformin .Myocardial infarction . Renal
function . Acute kidney injury
Introduction
Renal function may decline after primary percutaneous coro-
nary interventions (PCI) for ST-segment elevation myocardial
infarction (STEMI) as a result from impaired cardiac function,
initiation of pharmacotherapy, and contrast-induced nephrop-
athy. Contrast-induced acute kidney injury (CI-AKI) is ob-
served in approximately 15 % of the patients undergoing cor-
onary interventions for STEMI and is associated with in-
creased short- and long-term morbidity and mortality [1–7].
Although the exact pathophysiology is incompletely under-
stood, changes in renal circulation and subsequent tubular
damage are suggested to play a pivotal role [1, 2].
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The risk of renal dysfunction after PCI might be increased
by the extent of the underlying chronic and acute disease and
the use of co-medication, including the antihyperglycemic
agent metformin, which is used by millions of patients world-
wide for the treatment of type 2 diabetes [8–10]. However,
metformin is also associated with a lower risk of decline in
renal function in a general population of patients with type 2
diabetes [11–13]. This is of relevance since patients with renal
insufficiency are at increased risk of developing metformin-
associated lactic acidosis [10]. Metformin is therefore often
considered contraindicated since contrast agents may precipi-
tate acute kidney injury, thus allowing metformin and its me-
tabolites to accumulate and lead to lactic acidosis [14–16].
Because data are insufficient regarding the effect of metformin
on renal function in higher risk populations, such as after
STEMI, we examined whether metformin itself could ad-
versely affect renal function and consequently increase the
risk of developing lactic acidosis.
To determine whether metformin treatment initiated shortly
after myocardial infarction and subsequent iodinated contrast
exposure adversely affects renal function in patients without
known diabetes and without pre-existing renal dysfunction,
we assessed renal function and the incidence of CI-AKI as a
substudy of the Glycometabolic Intervention as Adjunct to
Primary Percutaneous Coronary Intervention in ST-Segment
Elevation Myocardial Infarction (GIPS) III trial [17].
Methods
Trial Design
The design and main results of the GIPS-III trial have been
published previously [17, 18]. Briefly, between January 2011
and May 2013, the double-blind GIPS-III trial randomized
380 adult patients who underwent primary PCI for STEMI
to receive a 4 month regimen with either 500 mg twice daily
metformin (191 patients) or a matching placebo (189 pa-
tients). The study medication was initiated as soon as possible
after PCI, with the aim of administering the first dose within
3 h after PCI. Exclusion criteria included previous myocardial
infarction, known diabetes, the need to perform coronary ar-
tery bypass graft surgery, severe renal dysfunction (creatinine
>2 mg/dl [177 μmol/L] at baseline), and contraindications for
(later) magnetic resonance imaging. During primary PCI, the
low-osmolar contrast agents Ioxaglate and Iobitridol were
used. Secondary treatment was according to current guidelines
[20]. Study medication was discontinued when subjects did
develop severe renal dysfunction (defined as creatinine
>2 mg/dl [177 μmol/L], or an estimated glomerular filtration
rate [eGFR] <30 ml/min/1.73 m2) [18].
The study protocol was in accordance with the Declaration
of Helsinki and was approved by the institutional review
board and national regulatory authorities (METc 2010.077).
Informed consent was obtained from all participants. This trial
was registered at ClinicalTrials.gov (Trial identifier:
NCT01217307).
Assessment of Renal Function
The measurements of serum creatinine concentrations were
planned at baseline, 6 h, 12 h, 24 h, 48 h, 2 weeks, 6 weeks,
and 4months after PCI [18]. For patients whowere returned to
their referring center after PCI, creatinine concentration mea-
surements during hospital admission and up to four months
were obtained. Estimated glomerular filtration rate (eGFR)
was calculated using the Chronic Kidney Disease Epidemiol-
ogy Collaboration study equation, as has been suggested to
estimate the GFR more accurate than the simplified Modifi-
cation of Diet in Renal Disease (sMDRD) formula in patients
without severe renal impairment [20, 21]. CI-AKIwas defined
as an increase in serum creatinine of ≥0.3 mg/dL (27 μmol/L),
or a 25 % relative rise in creatinine, within 48 h after the start
of the PCI procedure [1].
Statistical Analyses
Normally distributed continuous data are presented as
means with standard errors (SE), unless stated otherwise,
and differences were assessed using the Student’s t-test. If
normality could not be assumed, the data are presented as
medians with interquartile range (IQR), and differences
were assessed using the Mann-Whitney U test. Categori-
cal data are presented as frequencies with percentages,
and differences were assessed using the chi-square or
the Fisher exact test, when appropriate.
To estimate and compare the effect of metformin on renal
function, mixed-effects repeated measures analysis with ran-
dom slope and intercept was performed. This type of analysis
operates using estimation techniques that allow for incomplete
data. Age, gender, baseline N-terminal pro–B-type natriuretic
peptide (NT-proBNP) concentration, and myocardial blush
grade after PCI were, based on the statistical plan of the main
study, considered as covariables in relation to the renal func-
tion [17, 18]. Only significant covariables were used as fixed
effects in the final multivariate model. Individual patients
were considered as a random effect. The covariance matrix
of residuals used in the model was unstructured. To determine
the effect of metformin on renal function within the subset of
CI-AKI patients, we used a mixed-effects repeated measures
model similar to the primary analysis, but now including a
three way interaction variable including time, the occurrence
of CI-AKI, and treatment allocation.
The independent predictors of CI-AKI were identified by a
backward-stepwise logistic regression model using an entry
level of significance of 0.1. Randomization to metformin or
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placebo, gender, age, contrast dose, eGFR at baseline, and
anemia (Hb<13.7 mg/dl [<8.5 mmol/L] in men and Hb<
12.1 mg/dl [<7.5 mmol/L] in women) were previously asso-
ciated with the development of CI-AKI and were therefore
forced in the multivariate analysis in addition to risk factors
found in the univariate analysis [4, 8, 9, 22].
All reported P-values are 2-sided and P<0.05 was consid-
ered statistically significant, except for interactions in which
P<0.10 was considered significant. Statistical analyses were
performed by using SPSS Statistics for Windows, Version 22
(IBM, Armonk, NY) and Stata version 12.0 (Stata Corp., Col-




A total of 380 patients were randomized in the GIPS-III trial;
191 patients were allocated to the metformin treatment and
189 patients to placebo. Of those, 379 patients were included
in the present analysis (one patient, randomized to placebo,
withdrew informed consent), as depicted in Figure 1. A total
of 2582 serum creatinine measurements at the eight fixed time
points were available, with a median (range) of 7 (3–8) mea-
surements per patient. Serum creatinine concentration was
measured at baseline in 379 (100 %), at 6 h in 372 (98 %),
at 12 h in 365 (96 %), at 24 h in 297 (78 %), at 48 h in 154
(41 %), at 2 weeks in 346 (91 %), at 6 weeks in 336 (89 %),
and at 4 months in 333 (88%) patients, respectively. The main
reason for missing creatinine values at 48 h was early dis-
charge of low-risk patients (i.e., younger age, smaller myocar-
dial infarction size, better post-procedure myocardial perfu-
sion and left ventricular function, and no history of hyperten-
sion) and was not related to treatment allocation (109 [57.1 %]
of metformin vs. 116 [61.7 %] of placebo treated patients, P=
0.40), which is displayed in Online Resource 2.
Baseline characteristics were similar in both treatment
groups (Online Resource 3). The median duration until ad-
ministration of the first treatment dose after coronary interven-
tion was similar in the metformin group (102 min [IQR 81–
133]) and the control group (100 min [78–134], P=0.26). The
median duration of exposure to the study medication was also
similar in the metformin group (124 days [IQR 119–125]) and
the control group (124 days [IQR 120–125], P=0.14) [17].
Effect of Metformin on Renal Function
In the mixed-effects repeated-measures model analysis, sig-
nificant associations were found for age and baseline NT-
proBNP concentration, but not the overall interaction of time
and allocated treatment (P=0.27). From baseline up to four
months after PCI, the least-squares mean ± SE change in
eGFR was −6.5±0.8 ml/min/1.73 m2 in the overall popula-
tion. In none of the patients the study medication was
discontinued due to severe renal dysfunction.
Figure 2 displays the trends of adjusted eGFR over time in
patients randomized to metformin or placebo. In the first 48 h,
patients in both treatment groups experienced a rapid decrease
in mean eGFR of −7.2±0.8 ml/min/1.73 m2 in the metformin
group and −8.0±0.8 ml/min/1.73 m2 in the control group.
After 48 h, renal function slightly improved in both groups,
resulting in a mean overall decrease in eGFR of −5.9±0.8 ml/
min/1.73 m2 in the metformin group and −7.1±0.8 ml/min/
1.73 m2 in the control group from baseline to four months.
During hospitalization and at all scheduled visits, no signifi-
cant differences in adjusted eGFR were observed between the
two treatment groups (Online Resource 4).
During hospitalization and at all scheduled visits up to four
months after PCI, the unadjusted mean eGFR did not signif-
icantly differ in patients randomized to metformin or placebo
(Online Resource 5 and 6). When the sMDRD formula was
used to estimate the glomerular filtration rate, no significant
differences in renal function between patients randomized to
metformin or placebo were found during hospitalization and
all scheduled visits (Online Resource 6) [23]. A similar obser-
vation was made for serum creatinine concentrations (Online
Resource 6).
Contrast-Induced Acute Kidney Injury
CI-AKI was observed in 56 (14.8 %) patients; if CI-AKI was
defined as an increase in 0.5 mg/dl, 55 (14.5 %) patients de-
veloped CI-AKI. The clinical- and procedural characteristics,
cardiovascular history, and laboratory values at baseline in
patients who did and who did not develop CI-AKI are pre-
sented in Table 1. Patients who developed CI-AKI had a sig-
nificantly longer ischemic time, a longer coronary interven-
tion procedure, a higher baseline eGFR, a higher baseline
concentration of creatine kinase (CK), the myocardial band
of CK, and NT-proBNP. The CI-AKI group more frequently
used calcium channel blockers before admission, and more
frequently received coumarin derivatives and mineralocorti-
coid receptor antagonists (MRA) during hospitalization
(Table 2 and Online Resource 7). The incidence of CI-AKI
was similar in the metformin group (29 [15.2 %] patients) and
the control group (27 [14.4 %] patients, P=0.89).
Multivariate logistic regression analysis identified the ini-
tiation of a MRA during hospitalization as the strongest pre-
dictor of CI-AKI (odds ratio (OR): 3.30, 95%CI 1.51–7.23,
P<0.01), as presented in Table 3. In total, MRAs were started
in 38 (10.0 %) patients during hospitalization based on clinical
indication. At baseline, an increase in age (per 5 years), eGFR
(per 5 ml/min/1.72 m2), and logarithmic transformed NT-
proBNP concentration were also associated with an increased
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risk for CI-AKI. Randomization to metformin was not a pre-
dictor of CI-AKI (OR: 0.96, 95%CI 0.52–1.75, P=0.88).
When included in the multivariate analysis, contrast dose
was not associated with the development of CI-AKI (OR:
1.01 per 10 ml increase, 95%CI 0.98–1.03, P=0.60).
Mixed-effects repeated measures model analysis
showed no significant interaction between randomized
treatment, CI-AKI, and time with respect to the changes
in eGFR (P for interaction=0.14). Online Resource 8
displays the trends of adjusted eGFR over time in patients
with and without CI-AKI who were randomized to met-
formin or placebo. There was an expected overall interac-
tion between the occurrence of CI-AKI and the change in
eGFR over the first 48 h (P=0.021), but there was no
difference between randomized treatments (P=0.13). At
the end of follow up, eGFR did not differ between pa-
tients on placebo or metformin, neither in the CI-AKI
group (P=0.34) nor the no CI-AKI group (P=0.66).
Randomized after sucessful infarct-artery 
percutaneous coronary intervention
(n = 380)
Randomized to metformin 
(n = 191)
Included in present analysis 





Assessed for eligibility 
(n = 1473)
Excluded (n = 1093)
Note ligible (n = 1043)
Declined to participate (n = 37)
Enrolled in a different trial (n = 13)
Fig. 1 Flow of patients through
the glycometabolic intervention
as adjunct to primary coronary































Fig. 2 Presented are least-
squares means ± standard error
from the mixed-effects repeated
measurements model with a ran-
dom intercept and slope. Individ-
ual patients were considered as
random effects and the following
were fixed effects: age, baseline
N-terminal pro–B-type natriuretic
peptide concentration, and treat-
ment allocation. We assumed an
unstructured covariance structure
among serial estimated glomeru-
lar filtration rate values (eGFR).
No significant difference was ob-
served for the overall interaction
of time and allocated treatment
(P=0.27)
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Table 1 Characteristics of patients who did and did not develop contrast-induced acute kidney injury
No. (%)
Characteristic Total (n=379) CI-AKI (n=56) No CI-AKI (n=323) P-value
Metformin as study drug 191 (50.4) 29 (51.8) 162 (50.2) 0.89
Age at randomization, mean (SD), years 58.8 (11.6) 60.6 (11.6) 58.5 (12.1) 0.21
Women 95 (25.1) 19 (33.9) 76 (23.5) 0.13
Body mass indexa, mean (SD), kg/m2 27.0 (3.8) 26.6 (3.5) 27.0 (3.9) 0.41
Race/ethnicity 0.67
White 365 (96.3) 54 (96.4) 311 (96.3)
Asian 10 (2.6) 1 (1.8) 9 (2.8)
Black 4 (1.1) 1 (1.8) 3 (0.9)
Cardiovascular related history
Hypertension 112 (29.6) 20 (35.7) 92 (28.5) 0.27
Dyslipidemia 239 (63.1) 40 (71.4) 199 (61.6) 0.18
Current smoking 209 (55.1) 31 (55.4) 178 (55.1) 0.97
Stroke 3 (0.8) 0 3 (0.9) 1.00
Peripheral artery disease 0 0 0
Previous PCI 4 (1.1) 0 4 (1.2) 1.00
Blood pressure, mean (SD), mmHg
Systolic 134 (23) 136 (24) 134 (23) 0.59
Diastolic 84 (15) 86 (14) 84 (15) 0.46
Heart rate, mean (SD), beats/min 76 (16) 77 (15) 76 (17) 0.59
Anemiab 76 (20.1) 9 (16.1) 67 (20.7) 0.48
Ischemia time, median (IQR), min 161 (109–250) 218 (150–339) 150 (107–238) <0.01




146 (38.5) 24 (42.9) 122 (37.8)
Left circumflex coronary artery 64 (16.9) 11 (19.6) 53 (16.4)
Right coronary artery 169 (44.6) 21 (37.5) 148 (45.8)
Left main 0 0 0
Infarct related artery TIMI flow
Pre-intervention grade 0.06
0 208 (54.9) 37 (66.1) 171 (52.9)
1 27 (7.1) 5 (8.9) 22 (6.8)
2 66 (17.4) 5 (8.9) 61 (18.9)
3 78 (20.6) 9 (16.1) 69 (21.4)
Post-intervention grade 0.61
2 34 (9.0) 6 (10.7) 28 (8.7)
3 345 (91.0) 50 (89.3) 295 (91.3)
Myocardial blush grade 0.29
0 10 (2.6) 2 (3.6) 8 (2.5)
1 29 (7.7) 6 (10.7) 23 (7.2)
2 74 (19.5) 12 (21.4) 62 (19.4)
3 263 (69.4) 36 (64.3) 227 (70.9)
Procedural characteristics
Use of Ioxaglatec 373 (99.5) 56 (100) 317 (99.4) 1.00
Contrast dose, median (IQR), ml 150 (120–180) 150 (120–200) 140 (120–180) 0.06
Length of procedure,
median (IQR), min
31 (22–42) 36 (25–47) 30 (22–40) 0.04
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Table 1 (continued)
No. (%)
Characteristic Total (n=379) CI-AKI (n=56) No CI-AKI (n=323) P-value
Radiation exposure, median
(IQR), μGy/m2
5130 (2944–7646) 4791 (3643–7857) 5132 (2825–7645) 0.60
Laboratory values at admission
Creatinine, mean (SD), μmol/L 73 (15) 65 (15) 75 (15) <0.01
eGFRd, mean (SD), ml/min/1.73 m2 92 (16) 96 (15) 91 (16) 0.02
CK, median (IQR), U/L 129 (83–210) 156 (94–320) 125 (82–193) 0.03
Myocardial band of CK, median
(IQR), U/L
16 (13–25) 20 (14–42) 16 (12–23) <0.01
NT-proBNP, median (IQR), ng/L 81 (40–200) 126 (65–309) 75 (37–180) <0.01
Glucose, median (IQR), mmol/L 8.2 (7.0–9.6) 8.0 (7.3–9.5) 8.4 (7.0–9.6) 0.88
HbA1C, median (IQR), % 5.8 (5.6–6.0) 5.8 (5.7–6.0) 5.8 (5.6–6.0) 0.18
Hb, mean (SD), mmol/L 8.9 (0.8) 8.9 (0.8) 8.9 (0.8) 0.43
AUC from baseline up to 24 h
CK, median (IQR) 7.1×107 (3.0×107–15.1×107) 10.7×107 (3.3×107–19.5×107) 6.6×107 (2.9×107–14.1×107) 0.06
Myocardial band of CK,
median (IQR)
8.2×106 (3.4×106–15.8×106) 10.7×106 (3.6×106 –22.4×106) 7.8×106 (3.4×106–14.8×106) 0.09
CI-AKI contrast-induced acute kidney injury, SD standard deviation, PCI percutaneous coronary intervention, IQR interquartile range, TIMI thrombol-
ysis in myocardial infarction, CAG coronary arteriography, eGFR estimated glomerular filtration rate, CK creatine kinase, NT-proBNP N-terminal pro–
B-type natriuretic peptide, HbA1C glycated hemoglobin, Hb hemoglobin, AUC area under the curve
a Calculated as weight in kilograms, divided by lenght in meters squared.
b Defined as Hb<13.7 mg/dl (<8.5 mmol/L) in men and Hb<12.1 mg/dl (<7.5 mmol/L) in women.
c Type of contrast agent was known for 375 (98.9 %) patients
d Calculated using the Chronic Kidney Disease Epidemiology Collaboration study equation
Table 2 Medical therapy




No CI-AKI (n=323) P-value
Aspirin 341 (90.0) 48 (85.7) 293 (90.7) 0.24
Coumarin derivative 19 (5.0) 7 (12.5) 12 (3.7) 0.01
Thienopyridines 377 (99.5) 56 (100) 321 (99.4) 1.00
Clopidogrel 268 (70.7) 37 (66.1) 231 (71.5) 0.43
Prasugrel 4 (1.1) 2 (3.6) 2 (0.6) 0.11
Ticagrelor 105 (27.7) 17 (30.4) 88 (27.2) 0.63
ACE-inhibitor or ARB 263 (69.4) 41 (73.2) 222 (68.7) 0.54
Beta-blocker 323 (85.2) 51 (91.1) 272 (84.2) 0.22
Calcium-channel blocker 9 (2.4) 0 9 (2.8) 0.37
Mineralocorticoid receptor antagonist 38 (10.0) 13 (23.2) 25 (7.7) 0.01
Other diuretic 5 (1.3) 1 (1.8) 4 (1.2) 0.55
Statin 343 (90.5) 48 (85.7) 295 (91.3) 0.21
Insulina 5 (1.3) 1 (1.8) 4 (1.2) 0.55
Oral antihyperglycemic agenta 4 (1.1) 2 (3.6) 2 (0.6) 0.11
Values are expressed as n (%). Medical therapy initiated during hospitalization until hospital discharge for either
discharge home or transfer to a referring hospital. CI-AKI contrast-induced acute kidney injury, ARB angiotensin-
receptor blocker
a In addition to the study medication
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Discussion
In this predefined sub-analysis of the GIPS-III trial, changes in
renal function after primary PCI for STEMI were similar in
patients randomized to metformin or placebo.
Overall, eGFR declined during the 4 months of follow-up.
Several factors might influence this decrease in eGFR, such as
a reduction in left ventricular function after myocardial infarc-
tion and subsequent medical treatment, including the start of
ACE-inhibitors, angiotensin receptor blockers, and MRAs,
which are known to be associated with a decrease in eGFR
[1, 2, 24–26]. However, randomization to metformin treat-
ment had no effect on decrease in renal function compared
to placebo. In addition, no difference was observed in the
development of CI-AKI. To our knowledge, this is the first
placebo controlled study providing data suggesting that initi-
ation of metformin treatment early after primary PCI is safe in
patients without pre-existent renal dysfunction, which is in
line with animal- and studies suggesting metformin does not
adversely affect renal function or might even be protective by
reducing renal tubular damage [11–13, 27–29].
In our population, a higher incidence of CI-AKI was ob-
served when MRAs were initiated during hospitalization.
However, this association might be biased by the indication
of MRAs. The initiation of a MRA during hospitalization is
limited to patients with signs of heart failure and depressed left
ventricular function after STEMI [19]. Moreover, the initia-
tion of a MRA is associated with a steeper decline in renal
function in patients with heart failure after myocardial infarc-
tion [26].
Because of the exclusion of patients with known diabetes,
prior myocardial infarction, or pre-existing renal impairment,
the included patients had favorable baseline characteristics
and had a lower risk to develop renal dysfunction in compar-
ison to STEMI patients with these risk factors. Furthermore,
the median contrast dose of 150 ml was considerably lower
than previous studies evaluating patients who underwent PCI
for myocardial infarction [4, 6, 8, 22]. In our study, the inci-
dence of CI-AKI was around 15 % after 48 h, which is similar
to studies with a more heterogeneous patient population [4–6,
22]. Possibly, we observed a comparable incidence of CI-AKI
in our population because of the lower baseline creatinine
concentration and consequently, due to regression to the
mean, a higher chance of meeting the CI-AKI criteria [5, 6,
8, 22]. Therefore current CI-AKI criteria may not be the best
measure to identify renal dysfunction in lower risk STEMI
populations, such as ours. Also the termCI-AKImight wrong-
ly suggest that the cause of renal function decline is solely due
Table 3 Predictors for contrast-induced acute kidney injury
Univariate Multivariate
Characteristic OR (95%CI) P-value OR (95%CI) P-value
Randomization to metformin 1.07 (0.61–1.88) 0.82 0.96 (0.52–1.75) 0.88
Age (per 5 years increase) 1.08 (0.95–1.21) 0.24 1.31 (1.14–1.55) <0.01
Female sex 1.67 (0.91–3.07) 0.10
Ischemia time (per 5 mins increase) 1.01 (1.00–1.02) <0.01
Anemiaa 0.73 (0.34–1.57) 0.42
Pre-intervention TIMI-flow 0.79 (0.62–1.01) 0.06
Contrast dose (per 5 ml increase) 1.02 (1.00–1.05) 0.07
Length of procedure (per 5 mins increase) 1.05 (0.99–1.13) 0.13
eGFRb (per 5 ml/min/1.72 m2 increase) 1.12 (1.01–1.24) 0.03 1.33 (1.14–1.55) <0.01
CK (per 10 U/L increase) 1.01 (1.00–1.02) <0.01
Myocardial band of CK (per 5 U/L increase) 1.03 (1.01–1.06) <0.01
NT-proBNPc 2.08 (1.28–3.38) <0.01 1.91 (1.10–3.32) 0.02
Initiation of a coumarin derivative during hospitalizationd 3.70 (1.39–9.86) <0.01
Initiation of a MRA during hospitalizatione 3.60 (1.72–7.57) <0.01 3.30 (1.51–7.23) <0.01
When included in the multivariate analysis, contrast dose was not associated with the development of contrast-induced acute kidney injury (OR: 1.01 per
10 ml increase, 95%CI 0.98–1.03, P=0.60). OR odds ratio, 95%CI 95 % confidence interval, TIMI thrombolysis in myocardial infarction, eGFR
estimated glomerular filtration rate, CK creatine kinase, NT-proBNP N-terminal pro–B-type natriuretic peptide
a Defined as Hb <13.7 mg/dl (<8.5 mmol/L) in men and Hb <12.1 mg/dl (<7.5 mmol/L) in women
b Calculated using the Chronic Kidney Disease Epidemiology Collaboration study equation
c Log transformed
d In total, coumarine derivatives were initiated in 19 (5.0 %) patients during hospitalization on clinical indication
e In total, mineralocorticoid receptor antagonists were initiated in 38 (10.0 %) patients during hospitalization on clinical indication
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to contrast use, because myocardial ischemia also affects car-
diac function and the initiation of pharmacotherapy might
affect the estimated renal function parameters as well [25, 30].
Our findings may have an important clinical implication.
Due to an increased risk for lactic acidosis, metformin is cur-
rently often considered to be contraindicated in patients with
mild renal impairment until 48 h after procedures using iodin-
ated contrast agents [14–16]. During the study period, no
cases of lactic acidosis (lactate >5 mmol/L and pH <7.35)
were observed [17]. We believe that in patients without severe
renal impairment, metformin treatment can be started early
after the procedure [10, 31, 32]. Since this study only evalu-
ates the effect of metformin initiated shortly after PCI, further
investigation is needed to determine the safety or even protec-
tive effect of initiation of metformin prior to PCI or continu-
ation of metformin during PCI procedures.
We recognize that there are also limitations to our study.
First, metformin treatment was initiated after coronary inter-
vention, with a median delay of 101 min until the first dose of
study medication was administered, resulting in an average
time between contrast exposure and the achievement of effec-
tive plasma levels of approximately 4 h [17]. The lack of
beneficial effect of metformin on renal function might also
be attributable to the relatively low dose of metformin admin-
istered (500 mg twice daily). Second, the doses of contrast
agent used during the procedures were lower than in other
studies and were not associated with development of CI-
AKI after adjustment for covariates [4, 6, 8]. Finally, the
GIPS-III study excluded patients with severe renal impair-
ment, defined as a baseline creatinine level of >2 mg/dl
(177 μmol/L), which is the patient group that is most prone
to developing renal dysfunction [4, 8, 9, 22, 33]. Since the
majority of the study population were Caucasian and male,
generalizability of the results to females and other races will
be partly limited.
We conclude that the initiation of metformin shortly after
myocardial infarction and contrast exposure had no adverse
effect on renal function and did not influence the development
of CI-AKI in patients without diabetes and without prior renal
impairment undergoing primary PCI for STEMI. Metformin
use in higher risk patients deserves further investigation.
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